FEXUCLUE Trademark
FEXUCLUE is a USPTO trademark filed by DAEWOONG PHARMACEUTICAL CO., LTD.. Status: Registered.
Trademark Facts
| Mark | FEXUCLUE |
|---|---|
| Serial Number | 79335933 |
| Registration Number | 7123404 |
| Status | Registered |
| Filing Date | 2022-01-19 |
| Registration Date | 2023-08-01 |
| Mark Type | Combined |
| Nice Classes | 005 (Pharmaceuticals) |
| Owner | DAEWOONG PHARMACEUTICAL CO., LTD. |
| Attorney of Record | Diane J. Mason |
| Prosecution Events | 26 |
| Latest Event | FINO on 2023-11-27 |
Goods & Services
Pharmaceutical agents affecting digestive organs; medicines for treating intestinal disorders; Pharmaceutical preparations in the nature of proton-pump inhibitors for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger-Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection; medicines for the treatment of gastrointestinal diseases; medicines for human purposes for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger-Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection; pharmaceutical preparations for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger-Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection; ethical medicinal preparations for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger-Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection